Skip to content
value.today

Transposon Therapeutics, Inc.

🇺🇸 Westport, Connecticut, USAPharmaceuticalsFounded 2019
Total raised
$59 M
4 rounds on record
Latest round
$5 M
Jul 2024
First round on record
Apr 2020
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Transposon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$5 MNo. 4$2 to $10 million

Transposon Therapeutics, Inc.: Raise no. 4, Jul 2024

Investors in this round

8 investors had bought by the notice of Jul 15, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $20 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Taylor Podlesak · Executive Officer, Director
  • Eckard R. Weber, MD · Executive Officer, Director
  • Lynne R. Rollins · Executive Officer
  • Brent R. Ahrens · Director
  • Brian Taylor Slingsby, MD, PHD, MPH · Director
  • Daniel R. Hetu, MD, MBA · Director
  • John R. Pacifico · Director
  • Keith A. Katkin · Director
  • William R. Harrington, MD, MBA · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis G. Podlesak, Chief Executive Officer. Newest notice filed Jul 15, 2024. Read the notice at the SEC.

debt, optionsSEC
Dec 2022$5 MNo. 3$2 to $10 million

Transposon Therapeutics, Inc.: Raise no. 3, Dec 2022

Investors in this round

8 investors had bought by the notice of Jan 12, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $20 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eckard R. Weber, MD · Executive Officer, Director
  • Lynne R. Rollins · Executive Officer
  • Brent R. Ahrens · Director
  • Brian Taylor Slingsby, MD, PHD, MPH · Director
  • Daniel R. Hetu, MD, MBA · Director
  • Dennis Taylor Podlesak · Director
  • John R. Pacifico · Director
  • Keith A. Katkin · Director
  • William R. Harrington, MD, MBA · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne R. Rollins, Chief Financial Officer. Newest notice filed Jan 12, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2020$45 MNo. 2$10 to $50 million

Transposon Therapeutics, Inc.: Raise no. 2, Nov 2020

Investors in this round

10 investors had bought by the notice of Dec 9, 2020: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Preferred Stock and the underlying Common Stock issuable upon its conversion.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Podlesak · Executive Officer, Director
  • Eckard Weber, M.D. · Executive Officer, Director
  • Lynne R. Rollins · Executive Officer
  • Brent R. Ahrens · Director
  • John R. Pacifico · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne R Rollins, Chief Financial Officer. Newest notice filed Dec 9, 2020. Read the notice at the SEC.

equity, optionsSEC
Apr 2020$4 MNo. 1$2 to $10 million

Transposon Therapeutics, Inc.: Raise no. 1, Apr 2020

Investors in this round

4 investors had bought by the notice of May 6, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eckard Weber, M.D. · Executive Officer, Director
  • Lynne Rollins · Executive Officer
  • Brent Ahrens · Director
  • Dennis Podlesak · Director
  • John Pacifico · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne Rollins, CFO and Treasurer. Newest notice filed May 6, 2020. Read the notice at the SEC.

equity, debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Transposon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2024).

    SEC Form D · Jul 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Transposon Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Transposon Therapeutics, Inc.
NameRoleNamed in
Dennis Taylor PodlesakExecutive officerJul 2024
Eckard R. Weber, MDExecutive officerJul 2024
Lynne R. RollinsExecutive officerJul 2024
Dennis PodlesakExecutive officerDec 2020
Eckard Weber, M.D.Executive officerDec 2020
Lynne RollinsExecutive officerMay 2020
Brent R. AhrensDirectorJul 2024
Brian Taylor Slingsby, MD, PHD, MPHDirectorJul 2024
Daniel R. Hetu, MD, MBADirectorJul 2024
Dennis Taylor PodlesakDirectorJul 2024
Eckard R. Weber, MDDirectorJul 2024
John R. PacificoDirectorJul 2024
Keith A. KatkinDirectorJul 2024
William R. Harrington, MD, MBADirectorJul 2024
Dennis PodlesakDirectorDec 2020
Eckard Weber, M.D.DirectorDec 2020
Brent AhrensDirectorMay 2020
John PacificoDirectorMay 2020